IXHL - Psilocybin-Assisted Therapy Achieves Positive Clinical Trial Results For Treating Generalized Anxiety | Benzinga
Psilocybin-assisted therapy has hit a milestone as clinical trial results show potential benefits for Generalized Anxiety Disorder (GAD.)
With variable symptoms, the condition typically involves a person suffering from excessive anxiety and worry for over six months, potentially causing significant distress and impairment in social, occupational or other areas of functioning. A relatively common disorder, successful treatment of GAD remains inadequate, bringing on side effects and high costs.
The new topline clinical outcomes correspond to a Phase 2 study assessing psilocybin therapy's potential for treatment of Generalized Anxiety Disorder (GAD), conducted by clinical-stage cannabinoid and psychedelics biotech company Incannex Healthcare (NASDAQ:IXHL).
The trial met its primary endpoint, demonstrating a large clinical effect in the psilocybin treatment group over the placebo group:
- The psilocybin group showed a total 12.8 reduction in HAM-A* scores from baseline (29.5) to Week 11, or six weeks post-final dosing session (16.8).
- The psilocybin group's outcome represents a decrease of 9.2 points over the placebo group (3.6).
- 44% of patients in the psilocybin arm showed a clinically ...